The CHD3 (Chromodomain Helicase DNA-binding protein 3) antibody is a crucial tool for studying the CHD3 protein, a member of the CHD family of chromatin remodelers. CHD3. also known as Mi-2α, plays a vital role in regulating gene expression by altering chromatin structure through ATP-dependent nucleosome repositioning. It is a core component of the NuRD (Nucleosome Remodeling and Deacetylase) complex, which couples chromatin remodeling with histone deacetylase activity to repress transcription. CHD3 contains tandem chromodomains that recognize methylated histone tails and a helicase-like domain facilitating DNA unwinding, enabling its function in epigenetic regulation.
Research using CHD3 antibodies has linked the protein to diverse biological processes, including cell differentiation, DNA repair, and neural development. Mutations in the CHD3 gene are associated with neurodevelopmental disorders, such as CHD3-related intellectual disability syndrome, characterized by developmental delays, speech impairments, and distinct facial features. CHD3 dysregulation has also been implicated in cancers, including lymphoma and glioblastoma, where it may act as an oncogene or tumor suppressor depending on context.
CHD3 antibodies are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to investigate its expression, localization, and interactions. These studies help elucidate CHD3's role in maintaining chromatin architecture, mediating transcriptional repression, and contributing to disease pathogenesis.